Trial Profile
A study of JTX-2011 for the treatment of solid tumors.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 04 May 2023 According to a Jounce Therapeutics media release, Concentra Biosciences has completely acquired Jounce Therapeutics.
- 19 Apr 2016 New trial record